Why Older Kidneys Fail Under Stress and How Senescent Cells Drive Acute Kidney Injury
A JASN review links senescent cells, falling NAD+, and heme toxicity to why aging kidneys are prone to acute injury, and where senotherapies might help.
Summary
This review explains why older people are far more likely to suffer acute kidney injury (AKI). As the kidney ages, it accumulates senescent cells, which stop dividing but stay alive and release inflammatory, scarring and vessel-constricting signals. These signals can spread senescence to neighboring cells and distant organs. The review also lists other aging processes implicated in AKI: falling NAD+ content, reduced sirtuin expression, mitochondrial dysfunction, impaired autophagy, reduced expression of protective (nephroprotectant) proteins, and immune aging. In aged mice, clearing senescent cells with the senolytic ABT-263 improved kidney function and repair after injury. Old mice sharing a circulation with young mice also had milder AKI. The mechanistic evidence comes from mice. Human evidence is epidemiologic, showing AKI risk rising steeply with age. No senotherapy has yet been shown to prevent or treat AKI in people.
Detailed Summary
Aging kidneys are more vulnerable to acute kidney injury (AKI), and this review argues that cellular senescence is a central reason. Senescent cells have stopped dividing through upregulation of p16Ink4a and/or p21Cip1, but they remain metabolically active and resist apoptosis. They also secrete the senescence-associated secretory phenotype (SASP), a mix of inflammatory, fibrotic, cytotoxic and vasoconstrictive factors. Through the SASP, senescence can spread to neighboring cells and distant organs. The authors note that virtually all processes implicated in AKI at any age also occur as the kidney ages.
In humans, the evidence is epidemiologic. United States Renal Data System data from 2016 showed AKI rates more than doubled in people aged 80 to 84 and more than quadrupled above 85, compared with ages 66 to 69. Recurrent AKI within a year is more likely in older patients, and recovery of kidney function is impaired at 65 and older. About 20% of hospitalized Medicare patients with CKD and diabetes develop AKI each year. Dialysis-requiring AKI rose about 10% yearly from 2000 to 2009, but the percentage of older hospitalizations with dialysis-requiring AKI has more recently plateaued or fallen.
The mechanistic evidence comes from mice. - Aged mice show more senescence markers, SASP factors and fibrosis after ischemia-reperfusion injury (IRI) than young mice. - In aged mice, the senolytic ABT-263 cleared senescent cells. After IRI, treated mice showed higher GFR, more cell proliferation and regeneration, and less matrix expansion. - The same held in young mice given irradiation to raise their senescent cell burden. - Mice lacking p16Ink4a had milder AKI. INK4a/ARF-deficient kidneys transplanted into wild-type mice showed less fibrosis, and the recipients survived longer. - In parabiosis experiments, old mice joined to young mice had less severe AKI than old-old pairs. This implicates the aged systemic milieu, not only the kidney.
The authors propose that an old extrarenal environment is more susceptible to SASP factors from the injured kidney, which feeds back to worsen AKI.
Per the abstract, the review also covers heme as a prosenescent species and the role of senescence in the AKI-to-CKD transition. It discusses a set of age-related processes that overlap with AKI: vascular responses, diabetes, impaired NAD+ content, sirtuin expression, mitochondrial dysfunction, impaired autophagy, epigenetic changes, telomere shortening, impaired nephroprotectant expression, inflammaging and immunosenescence. It closes with the rationale for senolytics (which kill senescent cells) and senomorphics (which block SASP factors). The detailed sections on these topics fall beyond the supplied excerpt, so their specific data cannot be verified here.
Mechanism, function and lifespan should be read separately. In mouse AKI models, senescent cell clearance or p16 loss improved kidney function and repair. The lifespan evidence comes from a different setting: deleting p16-expressing cells in wild-type INK-ATTAC mice increased longevity and reduced age-related kidney injury, but this was not an AKI model. The review states that senolytics are effective in humans in vivo in general, but no human AKI outcome data are presented. The authors note it is unclear whether senescent cells by themselves cause AKI without other insults.
Caveats: this is a narrative review, not a systematic one. The mechanistic data are murine, human AKI evidence for senotherapy is absent from the excerpt, and the supplied text is truncated partway through the extrarenal-milieu section.
Key Findings
- Human data (USRDS 2016): AKI rates more than doubled at ages 80-84 and more than quadrupled above 85, compared with ages 66-69
- About 20% of hospitalized Medicare patients with CKD and diabetes develop AKI each year; recurrent AKI is more likely, and recovery is impaired, at age 65 and older
- Mouse mechanism: in aged mice, the senolytic ABT-263 cleared senescent cells and, after ischemia-reperfusion injury, increased GFR and regeneration and reduced matrix expansion
- Mouse function: old-young parabiosis produced less severe AKI than old-old pairing, implicating the aged systemic milieu
- Mouse genetics: p16Ink4a-deficient mice have less severe AKI, and INK4a/ARF-deficient kidney transplants show less fibrosis and better recipient survival
- Lifespan (separate from AKI): deleting p16-expressing cells in wild-type INK-ATTAC mice increased longevity and reduced age-related kidney injury
- Open question: the authors state it is unclear whether senescent cells by themselves cause AKI without other insults
Methodology
This is a narrative review. It synthesizes human epidemiologic data (USRDS, Medicare) with predominantly murine mechanistic studies: ABT-263 senolysis, p16Ink4a and INK4a/ARF knockouts, kidney transplantation and parabiosis. No formal search protocol, pooled analysis or quality grading is described. The supplied text is truncated in the extrarenal-milieu section. The sections on heme, NAD+/sirtuins, the AKI-to-CKD transition and senotherapies are known only from the abstract.
Study Limitations
The mechanistic evidence is mostly from mice, and human causal data for senescence in AKI are limited. The authors state it is unclear whether senescent cells cause AKI by themselves. The review is narrative, without formal grading. The supplied text is truncated, so the heme, NAD+, AKI-to-CKD and therapeutic sections could not be verified. No conflicts of interest were visible in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
